GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GB Sciences Inc (OTCPK:GBLX) » Definitions » Price-to-Owner-Earnings

GB Sciences (GB Sciences) Price-to-Owner-Earnings : (As of Jun. 06, 2024)


View and export this data going back to 2003. Start your Free Trial

What is GB Sciences Price-to-Owner-Earnings?

As of today (2024-06-06), GB Sciences's share price is $0.0096. GB Sciences does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for GB Sciences's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of GB Sciences was 170.00. The lowest was 0.00. And the median was 6.67.


GBLX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.81
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-06), GB Sciences's share price is $0.0096. GB Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.01. Therefore, GB Sciences's PE Ratio for today is At Loss.

As of today (2024-06-06), GB Sciences's share price is $0.0096. GB Sciences's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.00. Therefore, GB Sciences's PE Ratio without NRI for today is At Loss.

During the past 13 years, GB Sciences's highest PE Ratio without NRI was 6.50. The lowest was -2.50. And the median was 0.00.


GB Sciences Price-to-Owner-Earnings Historical Data

The historical data trend for GB Sciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GB Sciences Price-to-Owner-Earnings Chart

GB Sciences Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GB Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GB Sciences's Price-to-Owner-Earnings

For the Biotechnology subindustry, GB Sciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GB Sciences's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GB Sciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where GB Sciences's Price-to-Owner-Earnings falls into.



GB Sciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

GB Sciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.0096/-0.01
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GB Sciences  (OTCPK:GBLX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


GB Sciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of GB Sciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


GB Sciences (GB Sciences) Business Description

Traded in Other Exchanges
Address
9205 W. Russell Road, Suite 240, Las vegas, NV, USA, 89148
GB Sciences Inc is active in the healthcare sector. The company is engaged in developing and utilizing technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for a range of ailments.
Executives
John C Poss director, officer: Chief Executive Officer
Craig Ellins director, 10 percent owner, officer: CEO 3035 EAST PATRICK LANE, SUITE 9, LAS VEGAS NV 89120
Lazarus Management Co Llc 10 percent owner 260 N. JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Lazarus Israel Opportunities Fund Lllp 10 percent owner C/O IBEX GP LLC, 260 NORTH JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Lazarus Investment Partners Lllp 10 percent owner C/O IBEX INVESTORS LLC, 260 NORTH JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Justin B Borus 10 percent owner 260 N. JOSEPHINE STREET, SUITE 300, DENVER CO 80206

GB Sciences (GB Sciences) Headlines

From GuruFocus

Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives

By GuruFocusNews GuruFocusNews 12-06-2021

Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility

By GuruFocusNews GuruFocusNews 01-11-2022